Literature DB >> 15954853

Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.

Edgar L Schuck1, Hartmut Derendorf.   

Abstract

Pharmacokinetic/pharmacodynamic modeling has become an extremely important tool in evaluating and optimizing anti-infective therapy. By systematically linking the pharmacokinetic and pharmacodynamic properties of the anti-infective agent, it is possible to make educated decisions about the correct drug to be used, correct dosing regimen and to estimate the probability of success with the selected dose regimen. This article gives an overview of the current pharmacokinetic/pharmacodynamic approaches for anti-infective agents and discusses their use in optimizing drug therapy.

Mesh：

Substances：

Year:  2005        PMID： 15954853     DOI： 10.1586/14787210.3.3.361

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  16 in total

1.  Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.

Authors:  Elisabet I Nielsen; Anders Viberg; Elisabeth Löwdin; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

2.  A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro.

Authors:  Yanjun Li; M Hong Nguyen; Shaoji Cheng; Stephan Schmidt; Li Zhong; Hartmut Derendorf; Cornelius J Clancy
Journal:  Int J Antimicrob Agents       Date:  2008-01-22       Impact factor: 5.283

3.  Effect of protein binding on the pharmacological activity of highly bound antibiotics.

Authors:  Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

4.  Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.

Authors:  Subhajit Biswas; Soumi Sukla; Thomas Goldner; Hugh J Field; Dirk Kropeit; Daniela Paulsen; André Welbers; Helga Ruebsamen-Schaeff; Holger Zimmermann; Alexander Birkmann
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

5.  Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.

Authors:  Federico Pea; Pierluigi Viale; Piergiorgio Cojutti; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2012-10-08       Impact factor: 5.191

6.  In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis.

Authors:  Yabin Zhou; Ganggang Wang; Yutang Li; Yang Liu; Yu Song; Wenshuai Zheng; Ning Zhang; Xiaoyan Hu; Shikun Yan; Jihui Jia
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.

Authors:  Stephan Schmidt; Sreedharan Nair Sabarinath; April Barbour; Darren Abbanat; Prasarn Manitpisitkul; Sue Sha; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

Review 8.  Beyond conventional antibiotics - New directions for combination products to combat biofilm.

Authors:  Danir Fanisovich Bayramov; Jennifer Ann Neff
Journal:  Adv Drug Deliv Rev       Date:  2016-08-03       Impact factor: 15.470

9.  Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.

Authors:  Beate Henrichfreise; Irith Wiegand; Ingeborg Luhmer-Becker; Bernd Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

10.  A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.

Authors:  Nageshwar R Budha; Robin B Lee; Julian G Hurdle; Richard E Lee; Bernd Meibohm
Journal:  Tuberculosis (Edinb)       Date:  2009-09-11       Impact factor: 3.131
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.